Mitchell Chan - 01 Nov 2026 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
03 Nov 2026, 16:31:19 UTC
Prior SEC filing
03 Sep 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Patrick J. Christmas as attorney-in-fact
Filing notes and source

Key filing fact

Mitchell Chan filed Form 4 for REGENXBIO Inc. (RGNX) on 03 Nov 2026.

Key facts

  • This page summarizes Mitchell Chan's Form 4 filing for REGENXBIO Inc. (RGNX).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 03 Nov 2026, 16:31.

Change

  • Previous filing in this sequence was filed on 03 Sep 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001789335 Primary reporting owner

Chan Mitchell

Relationship
Chief Financial Officer
Address
C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE
Signature
/s/ Patrick J. Christmas as attorney-in-fact
Signature date
03 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RGNX transaction

Common Stock

Award

Transaction value
Shares
+24,305
Change %
+20%
Price
$0.000000*
Shares after
147,120
Date
01 Nov 2026
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 1/3rd of the shares subject to the RSU award shall vest on each of November 1, 2027, November 1, 2028, and November 1, 2029, while the recipient provides continuous service to the Issuer.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .